Cingulate Inc. — Form 8-K
Filed October 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Cingulate extended Chief Medical Officer Matthew N. Brams's trial period employment through December 31, 2026, at an annual base salary of $400,000 (full-time, 100% effort). The amendment preserves CEO discretion to return Brams to part-time status with lower compensation after the trial period concludes. No other material terms changed.
Why this rating
Executive compensation adjustment at $400K annually is ~2% of $19.4M market cap. Routine employment amendment with no material business impact disclosed.
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.